Healthcare · Pharmaceuticals & Biotechnology
QVM read Quality business Quality Strong, Valuation Expensive, Momentum Neutral
Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.
Sai Life Sciences Limited is an Indian contract research, development, and manufacturing organisation, headquartered in Hyderabad, Telangana. The company provides drug discovery, development, contract manufacturing services for small-molecule new chemical entities to pharmaceutical and biotechnology companies.
Source: Wikipedia
Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.
PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.
Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.
Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.
Ranks #22 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.
| Filed | Person | Category | Type | Quantity | Value |
|---|---|---|---|---|---|
| 26 Feb 2025 | TUNER GHOSH | Other | Sell | 0 | ₹0 |
| Date | Client | Deal | Action | Quantity | Price | Exchange |
|---|---|---|---|---|---|---|
| 30 Mar 2026 | MORGAN STANLEY ASIA SINGAPORE PTE | Block | Buy | 796,916 | 1015.4000 | NSE |
| 30 Mar 2026 | GOLDMAN SACHS BANK EUROPE SE - ODI | Block | Sell | 796,916 | 1015.4000 | NSE |
| 30 Mar 2026 | GOLDMAN SACHS BANK EUROPE SE - ODI | Block | Sell | 796,916 | 1015.4000 | NSE |
| 18 Sep 2025 | GOLDMAN SACHS BANK EUROPE SE - ODI | Block | Buy | 602,186 | 898.5000 | NSE |
| 18 Sep 2025 | GOLDMAN SACHS (SINGAPORE) PTE - ODI | Block | Sell | 602,186 | 898.5000 | NSE |
| 17 Sep 2025 | GOLDMAN SACHS BANK EUROPE SE - ODI | Block | Buy | 401,458 | 881.3500 | NSE |
| 17 Sep 2025 | GOLDMAN SACHS (SINGAPORE) PTE - ODI | Block | Sell | 401,458 | 881.3500 | NSE |
| 16 Sep 2025 | GOLDMAN SACHS BANK EUROPE SE - ODI | Block | Buy | 275,204 | 882.0000 | NSE |
| 16 Sep 2025 | GOLDMAN SACHS (SINGAPORE) PTE - ODI | Block | Sell | 275,204 | 882.0000 | NSE |
| 20 Jun 2025 | TPG ASIA VII SF PTE LTD | Block | Sell | 139,889 | 722.0000 | BSE |
Quarterly results, AGMs, buybacks and other board-approved business.
| Date | Purpose | Results |
|---|---|---|
| 6 Aug 2026 | Financial Results | Yes |
| 14 May 2026 | Financial Results | Yes |
| 5 Feb 2026 | Financial Results | Yes |
| 6 Nov 2025 | Financial Results | Yes |
| 7 Aug 2025 | Financial Results | Yes |
Exchange disclosures (NSE and BSE), most recent first.
Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.
Data unavailable.
Data unavailable.
Board of directors and corporate information →
Data unavailable (no single-stock futures or options activity on record for this company).
Part of: NIFTY 500, NIFTY 500, NIFTY PHARMA, NIFTY PHARMA
The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.
The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.
The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.
No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.
